3 May 2002 Source: http://www.access.gpo.gov/su_docs/aces/fr-cont.html ------------------------------------------------------------------------- [Federal Register: May 3, 2002 (Volume 67, Number 86)] [Notices] [Page 22414] From the Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr03my02-38] ----------------------------------------------------------------------- DEPARTMENT OF DEFENSE Department of the Army Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Method for Purifying Cholera Toxin AGENCY: Department of the Army, DoD. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of U.S. Patent No. 6,008,329 entitled ``Method for Purifying Cholera Toxin'' filed March 6, 1998. Foreign rights are also available (PCT/US99/05005). The United States Government as represented by the Secretary of the Army has rights in this invention. ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012. FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664, both at telefax (301) 619-5034. SUPPLEMENTARY INFORMATION: This invention relates to a method of purifying cholera toxin using a matrix with at least one ion chosen from among matrix with Ni+2, Co+2, Cd2 or Zn+2 immobilized thereon. It is possible thereby to selectively elute the B subunit for cholera toxin from the matrix. Luz D. Ortiz, Army Federal Register Liaison Officer. [FR Doc. 02-11071 Filed 5-2-02; 8:45 am] BILLING CODE 3710-08-M ----------------------------------------------------------------------- [Federal Register: May 3, 2002 (Volume 67, Number 86)] [Notices] [Page 22414] From the Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr03my02-39] ----------------------------------------------------------------------- [Federal Register: May 3, 2002 (Volume 67, Number 86)] [Notices] [Page 22412-22413] From the Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr03my02-33] ----------------------------------------------------------------------- DEPARTMENT OF DEFENSE Department of the Army Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Asporogenic B. ANTHRACIS Expression System AGENCY: Department of the Army, DOD. ACTION: Notice. ----------------------------------------------------------------------- [[Page 22413]] SUMMARY: In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of U.S. Patent No. 6,316,006 entitled ``Asporogenic B. ANTHRACIS Expression System'' issued November 13, 2001. The United States Government as represented by the Secretary of the Army has rights in this invention. ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21705-5012. FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664, both at telefax (301) 619-5034. SUPPLEMENTARY INFORMATION: This invention relates to a bacterial expression system for production of protective antigen (PA) against bacillus anthrasis. Recombinant asporogenic B. anthracits that are derived from Sterne-1(pPA102) and show inability to bind the dye when grown on Congo Red Agar can be screened and asporogenic strains isolated using methods of the invention. Organisms of the invention lacking spore-forming function may be killed by heat shock at temperatures as low as 60 deg.C. for 60 minutes. Hence, contamination of the environment with viable spore-forming organisms is easily avoided and decontamination is easily accomplished. Luz D. Ortiz, Army Federal Register Liaison Officer. [FR Doc. 02-11067 Filed 5-2-02; 8:45 am] BILLING CODE 3710-08-M ----------------------------------------------------------------------- DEPARTMENT OF DEFENSE Department of the Army Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning a Method of Making a Vaccine for Anthrax AGENCY: Department of the Army, DoD. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of U.S. Patent Application Serial No. 09/520,215 entitled ``Method of Making a Vaccine for Anthrax,'' filed March 7, 2000. The United States Government, as represented by the Secretary of the Army has rights in this invention. ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012. FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664, both at telefax (301) 619-5034. SUPPLEMENTARY INFORMATION: A method of making a vaccine from a protective antigen. The protective antigen is useful against Bacillus anthracis. The protective antigen is produced by an asporogenic organism, which overproduces the desired antigen. The asporogenic organism is a recombinant asporogenic B. anthracis. The recombinant asporogenic B. anthracis was derived from a Sterne-1(pPA102) strain of bacteria and binds to dye when grown on Congo Red Agar. Luz D. Ortiz, Army Federal Register Liaison Officer. [FR Doc. 02-11072 Filed 5-2-02; 8:45 am] BILLING CODE 3710-08-M ----------------------------------------------------------------------- [Federal Register: May 3, 2002 (Volume 67, Number 86)] [Notices] [Page 22413] From the Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr03my02-34] ----------------------------------------------------------------------- DEPARTMENT OF DEFENSE Department of the Army Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Burkholderia Toxins AGENCY: Department of the Army, DoD. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of U.S. Patent Application No. 09/770,714 entitled ``Burkholderia Toxins'' filed January 26, 2001. The United States Government as represented by the Secretary of the Army has rights in this invention. ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012. FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664, both at telefax (301) 619-5034. SUPPLEMENTARY INFORMATION: A novel composition comprising toxins produced from Burkholderia species is described and is effective in inhibiting nematode growth. Luz D. Ortiz, Army Federal Register Liaison Officer. [FR Doc. 02-11066 Filed 5-2-02; 8:45 am] BILLING CODE 3710-08-M -----------------------------------------------------------------------